VEGFR2/KDR/Flk-1 Antibody (KDR657), Novus Biologicals™

VEGF R2/KDR/Flk-1

Flow Cytometry 0.5 - 1ug/million cells in 0.1ml, Immunofluorescence 0.5 - 1ug/ml

Monoclonal

Purified

RUO

Human

P35968

3791

Recombinant human VEGF-R2 protein

Primary

Store at 4C.

KDR657

Flow Cytometry, Immunofluorescence

Unconjugated

Mouse

Angiogenesis, Cancer, Cellular Markers, Endothelial Cell Markers, Hematopoietic Stem Cell Markers, HIF Target Genes, Hypoxia, Phospho Specific, Signal Transduction, Stem Cell Markers, Tumor Suppressors, Tyrosine Kinases

PBS with 0.05% BSA. with 0.05% Sodium Azide

CD309, CD309 antigen, EC 2.7.10, EC 2.7.10.1, Fetal liver kinase 1, fetal liver kinase-1, FLK-1, FLK1tyrosine kinase growth factor receptor, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, vascular endothelial growth factor receptor 2, VEGFR, VEGFR2, VEGFR-2

KDR

IgG1 κ

Protein A purified

CD309, also known as VEGF-R2, KDR3, and Flk-1 (mouse), is a type I transmembrane glycoprotein. It is a member of the CSF-1/PDGF receptor family of type III tyrosine kinase receptors. Human VEGF-R2 is mainly expressed by endothelial cells, embryonic tissues, and megakaryocytes. It plays an important role in the regulation of angiogenesis, vasculogenesis, and vascular permeability. The ligands of VEGF-R2 include VEGF-A, VEGF-C, VEGF-D, and VEGF splice isoforms. Ligation of VEGF-R2 with its ligands results in the receptor dimerization and auto-phosphorylation, stimulating endothelial cell proliferation and migration.